114 related articles for article (PubMed ID: 20126849)
1. IGF-I, insulin and prostate cancer.
Lima GA; Corrêa LL; Gabrich R; Miranda LC; Gadelha MR
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):969-75. PubMed ID: 20126849
[TBL] [Abstract][Full Text] [Related]
2. IGFs and human cancer: implications regarding the risk of growth hormone therapy.
Shim M; Cohen P
Horm Res; 1999; 51 Suppl 3():42-51. PubMed ID: 10592443
[TBL] [Abstract][Full Text] [Related]
3. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
4. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
5. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-I and binding protein-3 and risk of cancer.
Giovannucci E
Horm Res; 1999; 51 Suppl 3():34-41. PubMed ID: 10592442
[TBL] [Abstract][Full Text] [Related]
7. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
Chokkalingam AP; Pollak M; Fillmore CM; Gao YT; Stanczyk FZ; Deng J; Sesterhenn IA; Mostofi FK; Fears TR; Madigan MP; Ziegler RG; Fraumeni JF; Hsing AW
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer.
Chan JM; Stampfer MJ; Ma J; Gann P; Gaziano JM; Pollak M; Giovannucci E
J Natl Cancer Inst; 2002 Jul; 94(14):1099-106. PubMed ID: 12122101
[TBL] [Abstract][Full Text] [Related]
10. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence?
Meinbach DS; Lokeshwar BL
Urol Oncol; 2006; 24(4):294-306. PubMed ID: 16818181
[TBL] [Abstract][Full Text] [Related]
12. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study.
Wolk A; Mantzoros CS; Andersson SO; Bergström R; Signorello LB; Lagiou P; Adami HO; Trichopoulos D
J Natl Cancer Inst; 1998 Jun; 90(12):911-5. PubMed ID: 9637140
[TBL] [Abstract][Full Text] [Related]
15. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
Miyata Y; Sakai H; Hayashi T; Kanetake H
Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
[TBL] [Abstract][Full Text] [Related]
16. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-I and prostate cancer: a meta-analysis.
Shi R; Berkel HJ; Yu H
Br J Cancer; 2001 Sep; 85(7):991-6. PubMed ID: 11592771
[TBL] [Abstract][Full Text] [Related]
18. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
[TBL] [Abstract][Full Text] [Related]
19. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
Stattin P; Rinaldi S; Biessy C; Stenman UH; Hallmans G; Kaaks R
J Clin Oncol; 2004 Aug; 22(15):3104-12. PubMed ID: 15284261
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer and acromegaly.
Corrêa LL; Lima GA; Paiva HB; Silva CM; Cavallieri SA; Miranda LC; Gadelha MR
Arq Bras Endocrinol Metabol; 2009 Nov; 53(8):963-8. PubMed ID: 20126848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]